Showing 2291-2300 of 2652 results for "".
- Early Study Shows J&J’s One-Dose COVID-19 Vaccine Triggered Antibodies in all Participantshttps://modernod.com/news/early-study-shows-jjs-one-dose-covid-19-vaccine-triggered-antibodies-in-all-participants/2478759/Detailed phase 1/2a study findings published in the NEJM on Wednesday showed that all volunteers given Johnson & Johnson’s single-dose coronavirus vaccine Ad26.COV2.S had detectable neutralizing antibodies by day 57. In September, the company reported a preview of the interim results in
- Johnson & Johnson Vision Releases New Guide to Help Slow the Progression of Myopia in Childrenhttps://modernod.com/news/johnson-johnson-vision-releases-new-guide-to-help-slow-the-progression-of-myopia-in-children/2478750/Johnson & Johnson Vision announced a new guide with recommendations for eye care professionals to assess, monitor and treat myopia in children. The guide, titled “Managing Myopia: A Clinical Response to the Growing Epidemic,” is a result of a year of collaboration with lead
- JPM: BioNTech Hikes COVID-19 Vaccine Output to 2B Doses in 2021—And Plans a Bigger Label, Toohttps://modernod.com/news/jpm-biontech-hikes-covid-19-vaccine-output-to-2b-doses-in-2021-and-plans-a-bigger-label-too/2478746/With its Pfizer-partnered COVID-19 vaccine authorized in the U.S., Europe, the U.K. and a slate of other countries, German mRNA specialist BioNTech is wasting no time scaling up its 2021 pandemic ambitions—namely, 2 billion shots by year-end, plus a slate of new approvals and a temperature-stable
- EnChroma Names Vision Industry Veteran Erik Ritchie as CEOhttps://modernod.com/news/enchroma-names-vision-industry-veteran-erik-ritchie-as-ceo/2478743/EnChroma, creators of EnChroma eyewear for color blindness, named Erik Ritchie as its CEO. Mr. Ritchie brings 25 years of experience in the optical industry and other fields. Most recently, he served as Chief Commercial Officer for Zenni Optical, the largest online provider of prescription eyewea
- CorNeat Vision’s First Patient Regains Sight Following Artificial Cornea Implantation at Rabin Medical Centerhttps://modernod.com/news/corneat-visions-first-patient-regains-sight-following-artificial-cornea-implantation-at-rabin-medical-center/2478741/The CorNeat KPro, an artificial cornea that integrates with the eye wall with no reliance on donor tissue, was successfully implanted in a human. The surgery was performed on a bilaterally blind, 78-year-old male at Rabin Medical Center, Israel, by Professor
- Moderna Boosts COVID-19 Vaccine Output for 2021 to at Least 600 Million Doseshttps://modernod.com/news/moderna-boosts-covid-19-vaccine-output-for-2021-to-at-least-600-million-doses/2478715/Moderna said it expects to produce a minimum of 600 million doses of its COVID-19 vaccine mRNA-1273 globally this year, up from an earlier estimate of 500 million, and that it is still working to build up to potentially 1 billion doses for 2021. The company also plans to deliver about 100 million
- WHO Validates Pfizer, BioNTech’s COVID-19 Vaccine for Emergency Usehttps://modernod.com/news/who-validates-pfizer-biontechs-covid-19-vaccine-for-emergency-use/2478709/The World Health Organization (WHO) said Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 became the first vaccine to receive WHO validation for emergency use since the pandemic began. According to the WHO, BNT162b2 has met the agency’s “must-have” criteria for safety and e
- From COVID-19 to Retail Health: Fierce Healthcare’s Biggest Stories of 2020https://modernod.com/news/from-covid-19-to-retail-health-fierce-healthcares-biggest-stories-of-2020/2478689/The year 2020 was dominated by the fallout from a generational global pandemic. So perhaps it’s no surprise that COVID-19 headlines also governed much of
- Genentech’s Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase 3 Studies for DMEhttps://modernod.com/news/genentechs-faricimab-meets-primary-endpoint-and-shows-strong-durability-across-two-global-phase-3-studies-for-dme/2478687/Genentech announced positive topline results from two identically designed global phase 3 studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME). Both studies met their primary endpoint and showed that
- FDA Panel Endorses Moderna’s COVID-19 Vaccine for Emergency Usehttps://modernod.com/news/fda-panel-endorses-modernas-covid-19-vaccine-for-emergency-use/2478678/An FDA advisory panel on Thursday voted 20-0, with one abstention, that the benefits of Moderna’s COVID-19 vaccine mRNA-1273 outweigh its risks in people 18 years and older. The panel backing sets the stage for the FDA to issue an emergency-use authorization (EUA) for the candidate, which i